Stock listing
Frankfurt:9II Biovica International AB Aktie
German listing (Frankfurt) of Biovica International AB · home listing Stockholm:BIOVICB
Follow Biovica International AB into a list and get an email when it puts out news.
Share price · FWB:9II
€0.018 EUR +0.000 (+1.1%)
Close on Oct 27, 2026
- Day range
- €0.018 – €0.018 EUROct 27, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| Frankfurt:9II | €0.018 EUR | +0.000 (+1.1%) | — | €0.018 | €0.018 | €0.018 | €0.018 | Close on Oct 27, 2026 |
- Ticker
- Frankfurt:9II
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 16, 2026
Announcement from the Annual General Meeting in Biovica International AB
Latest earnings call · Sep 10, 2026
Biovica International (Stockholm:BIOVIC B) Q1 2027 Earnings Call
Replay and transcript
Calls
Replays
Biovica International (Stockholm:BIOVIC B) Q1 2027 Earnings Call
Thu, Sep 10, 2026 · 9:00 AM ET
Watch TranscriptBiovica International (Stockholm:BIOVIC B) Q3 2026 Earnings Call
Wed, Mar 18, 2026 · 9:00 AM ET
Watch TranscriptBiovica International (Stockholm:BIOVIC B) Q1 2026 Earnings Call
Thu, Sep 11, 2025 · 9:00 AM ET
Watch Transcript
Latest news
Financings
Rights offering of b-shares
Sep 9, 2026 · US$3.05M
Announced: about SEK 29.2M · SEK 0.3 a share · Zonda Partners AB
Dealers: Zonda Partners AB
Buyers: HDF (Subscription commitment (with two other shareholders, about SEK 7.92 million in total) and guarantee undertaking of a maximum of approximately SEK 21.21 million, 72.67 percent of the Rights Issue); Cornelia Willemina Kuijvenhoven (Subscription commitment, part of approximately SEK 7.92 million total with HDF and Cornelis Jan Bogerd); Cornelis Jan Bogerd (Subscription commitment, part of approximately SEK 7.92 million total with HDF and Cornelia Willemina Kuijvenhoven); Cornelis Peter Bogerd (Intends to subscribe for his pro rata share, 0.18 percent of the Rights Issue)
Insiders: Board member Cornelis Peter Bogerd intends to subscribe for his pro rata share (0.18 percent); CEO Theis Kipling and board members Fredrik Alpsten and Jesper Söderqvist intend to subscribe for about SEK 0.5 million (1.68 percent).
Use of proceeds: Working capital: about 50 percent to continue US commercialisation of DiviTum TKa and about 50 percent to expand the pharma service offering.
Decks
Q4 2025 Earnings Presentation
Earnings · 37 slides · Jun 18, 2025
Q3 2025 Earnings Presentation
Earnings · 30 slides · Mar 13, 2025
Q2 2025 Earnings Presentation
Earnings · 37 slides · Dec 12, 2024
Q1 2025 Earnings Presentation
Earnings · 31 slides · Sep 12, 2024
Biovica International AB on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 4 in the last 12 months · 15 in all · newest Sep 16, 2026 · oldest 2025
- Calls
- 11 calls with a replay · 11 with a transcript · latest Sep 10, 2026
- Decks
- 20 decks · latest Jun 18, 2025
Where Biovica International AB is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| Stockholm:BIOVICB · Home listing | Stockholm | Sweden | SEK |
| LS Exchange:A2DPS4 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2DPS4 | Lang & Schwarz | Germany | EUR |
| gettex:9II | gettex | Germany | EUR |
| Munich:9II | Munich | Germany | EUR |
| Frankfurt:9II · This page | Frankfurt | Germany | EUR |
| Stuttgart:9II | Stuttgart | Germany | EUR |
Log in to ask 6ix AI your own questions about Biovica International AB.